JCPyV-specific T Cell Therapy(Cellevolve)

N/A

Report date: 2022/12/10 22:20:06

Base Information

Drug NameJCPyV-specific T Cell Therapy(Cellevolve)

Drug Alias NameCE-VST01-JC(Cellevolve)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Virus-specific T Cell therapy

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsLeukoencephalopathy, Progressive Multifocal

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesCellevolve Bio Inc

China Registration ClassN/A

Develop Information

Active CompaniesCellevolve Bio Inc

Inactive CompaniesN/A

Active IndicationsLeukoencephalopathy, Progressive Multifocal

Inactive IndicationsN/A

Other Information

ATC CodeN/A